Primary Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Metastatic Cutaneous Squamous Cell Carcinoma

Main Article Content

Danny Rischin
Michael R Migden
Anne Lynn S Chang
Et al.



Abstract not available.


Disclosures: Study sponsored by Regeneron Pharmaceuticals and Sanofi.


Copyright 2018 SKIN

Most read articles by the same author(s)

1 2 3 > >>